The first product from the skincare platform, H2GLOW, keeps two serums separate until the first use.
Alchemy 21/12 has introduced Oleotide, a skincare formulation platform that will debut in H2GLOW, a 14-day treatment. The California company plans to release an initial run of 200 units on 30 November 2026, with worldwide availability planned for 2027.
Two serums in one treatment
H2GLOW stores its two serums in separate chambers. They combine at first use to make a single 10 mL treatment intended for morning and evening application. The design lets the company formulate each serum separately before they are mixed.
Alchemy 21/12 says the treatment is designed to address the appearance of wrinkles and improve firmness, texture, brightness and tone. The company said clinical evaluation was still underway when it announced the product.
A platform for more than one format
Oleotide groups formulation ingredients by their intended roles, from supporting the skin barrier to addressing the appearance of firmness. Alchemy 21/12 says it can vary the emphasis of those roles from one product to another. Four additional products using the platform are in development for 2027.